bioAffinity Technologies Appoints New Chief Science Officer

0
9

SAN ANTONIO– bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Senior Vice President of Research and Development, Dr. Bauta was the Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of therapeutics in the companies’ pipelines, and Manager of Medicinal and Process Chemistry at Southwest Research Institute.

Dr. Bauta is responsible for multiple Company inventions and patents supporting bioAffinity’s diagnostic and therapeutic advancements, including improvements to optimize CyPath® Lung, the Company’s noninvasive test to detect early-stage lung cancer, that both improved performance and cut costs. His discoveries have expanded the Company’s patent portfolio and added to a growing list of publications. In addition to bioAffinity patents on which he is a named inventor, he holds multiple healthcare-related patents and has published in more than a dozen scientific journals, including the journal Science.

“Dr. Bauta brings both scientific rigor and business acumen to the CSO position as we accelerate the commercial rollout of our CyPath® Lung test and expand our development pipeline. He will work with an exceptional scientific team who developed our high throughput, automated diagnostic platform to accurately analyze the lung microenvironment, allowing us to advance new technologies that can detect early-stage diseases. He is focused on making our products important steps in the care pathway for diagnosing early-stage disease,” bioAffinity President and CEO Maria Zannes said.

Dr. Bauta earned his Ph.D. from the University of Chicago where he received fellowships from the National Science Foundation and the American Chemical Society. His post-doctoral studies were at the University of Texas at Austin under a National Institutes of Health fellowship.

Dr. Bauta succeeds Vivienne I. Rebel, M.D., Ph.D. who retired from her position on Oct. 31, 2024, as Executive Vice President and Chief Science and Medical Officer. Dr. Rebel joined the Company in 2016 and led the research and development of CyPath® Lung.

“We wish Dr. Rebel the very best in retirement,” said Zannes. “Vivienne has made an indelible mark on us all. Her scientific precision and innovative spirit will remain a hallmark of bioAffinity Technologies.”

Leave A Reply

Please enter your comment!
Please enter your name here